In this Dec.18, 2014, photograph, scientist Christopher Kistler checks on experiments in bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. On June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study.
In this Dec.18, 2014, photograph, scientist Christopher Kistler checks on experiments in bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. On June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study. Mel Evans AP
In this Dec.18, 2014, photograph, scientist Christopher Kistler checks on experiments in bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. On June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study. Mel Evans AP